011 Correlation Between Validated Instruments Used in the RECONNECT Studies

Hypoactive sexual desire disorder (HSDD) is the most common sexual dysfunction in women, and is characterized by an absence or deficiency of sexual desire accompanied by personal distress. Bremelanotide, a melanocortin receptor agonist, is approved for the treatment of acquired, generalized HSDD in premenopausal women. The RECONNECT studies demonstrated that subcutaneous self-administration of bremelanotide, as needed, significantly improved sexual desire and decreased related personal distress in premenopausal women with HSDD. Sexual desire was assessed using validated instruments such as the Female Sexual Function Index-desire domain (FSFI-D) and the Elements of Desire Questionnaire (EDQ), which allow for measurement of additional elements of sexual desire and interest not captured by the FSFI, such as intensity of sexual desire, thoughts/fantasies about sex, and receptivity to sexual requests.